20.500.12556/RUL-147250 Treatment of osteoporosis with teriparatide the Slovenian experience The aim of this study was to investigate the characteristics of postmenopausal women prescribed with teriparatide in Slovenia, during the first decade after its approval, and the predictors of bone mineral density (BMD) improvement with treatment. We retrospectively studied postmenopausal osteoporotic patients prescribed with teriparatide at tertiary center from 2006 to 2015. BMD was measured at standard sites by DXA at baseline, after 12 and 24 months. 25-hydroxyvitamin D and procollagen type I N-terminal propeptide (PINP) were measured at the same time-points. The inclusion criteria were met by 188 women (aged 71 years on average), 151 (80.3%) with postmenopausal and 37 (19.7%) with glucocorticoid-induced osteoporosis. Everyone had at least one fracture, 159 (84.6%) had ≥2 fractures, with vertebral fractures in 172 patients (91.5%). All patients had been previously on antiresorptives for 8.6 years on average. The average BMD change at lumbar spine, total hip, and femoral neck was +5.0%, −1.1%, and +0.3% after 24 months of treatment, respectively. Higher baseline PINP was associated with higher BMD increase at all sites after the first 12 months. Teriparatide was prescribed mostly to elderly women with severe osteoporosis who had sustained two or more fractures despite long-term antiresorptive therapy. Baseline PINP might predict initial BMD increase with teriparatide. bisphosphonates bone mineral density osteoporosis teriparatide postmenopavza osteoporoza teriparatide kostna gostota biofosfonati true false true Angleški jezik Slovenski jezik Članek v reviji 2023-06-28 08:17:38 2023-06-28 08:17:39 2023-06-29 03:40:30 0000-00-00 00:00:00 2021 0 0 Str. 1544-1551 iss. 1 Vol. 16 2021 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.4 2391-5463 10.1515/med-2021-0359 81384707 10.1515_med-2021-0359.pdf 10.1515_med-2021-0359.pdf 1 8E297525B2D256719CDAD7E26EC2EEEC af43746ce6e3e356224eff3ad09d02ebcb243d0a729be1015c95361cc8cc7e40 20d4732e-157c-11ee-a314-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=170759 https://www.degruyter.com/document/doi/10.1515/med-2021-0359/html 1 171cb3e2-157b-11ee-a314-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=170758 Medicinska fakulteta Fakulteta za farmacijo 0 0 0